{"canonical":"https://abierto.us/vendors/eydis-bio-inc-mwwcm7jmbcf1","key":"MWWCM7JMBCF1","name":"EYDIS BIO, INC.","uei":"MWWCM7JMBCF1","city":"DURHAM","state":"NC","awards":1,"obligated":"0","notices_won":0,"top_agency_name":"National Institutes of Health","top_naics":"541714","cage":"88U01","parent_name":"EYDIS BIO, INC.","also_known_as":[],"country":"USA","actions":1,"first_action":"2026-09-02","last_action":"2026-09-02","breakdowns":{"naics":[{"key":"541714","name":null,"awards":1,"obligated":"0.00"}],"places":[{"key":"NC","name":null,"awards":1,"obligated":"0.00"}],"agencies":[{"key":"7529","name":"National Institutes of Health","awards":1,"obligated":"0.00"}],"set_asides":[{"key":"SMALL BUSINESS SET ASIDE - TOTAL","name":null,"awards":1,"obligated":"0.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":1,"obligated":"0.00"}],"competition":[{"key":"FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES","name":null,"awards":1,"obligated":"0.00"}],"product_service_codes":[{"key":"AN12","name":null,"awards":1,"obligated":"0.00"}]},"awards_list":[{"award_key":"CONT_AWD_75N93025C00040_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75N93025C00040_7529_-NONE-_-NONE-/","piid":"75N93025C00040","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"MWWCM7JMBCF1","recipient_name":"EYDIS BIO, INC.","recipient_uei":"MWWCM7JMBCF1","recipient_cage":"88U01","recipient_city":"DURHAM","recipient_state":"NC","sub_name":"National Institutes of Health","office_name":"NATIONAL INSTITUTES OF HEALTH NIAID","office_key":"o-75N930","first_action_date":"2026-09-02","last_action_date":"2026-09-02","actions":1,"obligated":"0","current_total_value":"499825.00","potential_total_value":"499825.00","naics":"541714","psc":"AN12","extent_competed":"FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES","set_aside":"SMALL BUSINESS SET ASIDE - TOTAL","offers_received":1,"description":"PERFORM A STRUCTURE ACTIVITY RELATIONSHIP (SAR), MOLECULAR BINDING AND METABOLISM OF THE LEAD SCAFFOLD (HS-176) TO GUIDE THE DEVELOPMENT OF MORE POTENT AND DRUG LIKE ANALOGS, AND PRIORITIZATION OF LEAD ANALOGS THROUGH IN VITRO EFFICACY SCREENING AND","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":1,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}